

## ESM Tables

**ESM Table 1 Correlation between HOMA2-B, HOMA2-IR and C-peptide, HDL-cholesterol in DCS and ANDIS.**

<b>HOMA measure</b>	<b>Var</b>	<b>Cohort</b>	<b><math>\rho</math></b>
HOMA2-IR	C-peptide	DCS	0.98
		ANDIS	0.93
HOMA2-B	C-peptide	DCS	0.63
		ANDIS	0.62
HOMA2-IR	HDL-cholesterol	DCS	-0.22
		ANDIS	-0.27
HOMA2-B	HDL-cholesterol	DCS	-0.10
		ANDIS	-0.05


Correlation coefficient based on spearman's Rho.

**ESM Table 2 Sensitivity and specificity of the cross-validation of clusters in other studies.**


Group	Sensitivity	Specificity	Cohort	Centres
1/SIDD	96.22[94.98-97.23]	98.62[98.3-98.89]	GoDARTS	ANDIS
1/SIDD	97.06[94.8-98.52]	97.32[96.63-97.91]	ANDIS	DCS
1/SIDD	85.64[83.52-87.59]	99.63[99.45-99.77]	DCS	ANDIS
1/SIDD	88.78[86.61-90.72]	98.59[98.21-98.92]	ANDIS	GoDARTS
1/SIDD	77.57[74.79-80.18]	99.19[98.88-99.43]	DCS	GoDARTS
1/SIDD	97.06[94.8-98.52]	96.36[95.56-97.04]	GoDARTS	DCS
2/SIRD	92.29[90.05-94.15]	92[91.33-92.64]	GoDARTS	ANDIS
2/SIRD	36.05[32.32-39.91]	94.43[93.41-95.33]	ANDIS	DCS
2/SIRD	68.57[64.99-72]	82.75[81.83-83.65]	DCS	ANDIS
2/SIRD	56.19[53.02-59.33]	99.29[99-99.52]	ANDIS	GoDARTS
2/SIRD	83.42[80.94-85.7]	89.67[88.75-90.54]	DCS	GoDARTS
2/SIRD	64.26[60.41-67.99]	94.25[93.23-95.17]	GoDARTS	DCS
3/MOD	76.01[73.93-78]	98.45[98.1-98.75]	GoDARTS	ANDIS
3/MOD	73.85[69.84-77.57]	85.16[83.69-86.55]	ANDIS	DCS
3/MOD	54.96[52.58-57.32]	95.73[95.18-96.24]	DCS	ANDIS
3/MOD	93.21[91.53-94.65]	92.72[91.91-93.46]	ANDIS	GoDARTS
3/MOD	62.87[59.88-65.78]	96.27[95.67-96.81]	DCS	GoDARTS
3/MOD	74.23[70.24-77.94]	91.62[90.44-92.69]	GoDARTS	DCS
4/MD	66.15[64.3-67.96]	91.53[90.71-92.3]	GoDARTS	ANDIS
4/MD	51.04[47.65-54.42]	74.46[72.53-76.32]	ANDIS	DCS
4/MD	40.82[38.93-42.73]	81.04[79.91-82.13]	DCS	ANDIS
4/MD	78.14[75.95-80.21]	83.13[81.93-84.27]	ANDIS	GoDARTS
4/MD	67.81[65.37-70.17]	86.96[85.88-87.99]	DCS	GoDARTS
4/MD	66.74[63.5-69.88]	87.83[86.35-89.2]	GoDARTS	DCS
5/MDH	92.75[91.15-94.13]	94.18[93.57-94.74]	GoDARTS	ANDIS
5/MDH	73.33[69.45-76.97]	98.54[97.98-98.98]	ANDIS	DCS
5/MDH	92.91[91.33-94.28]	92.71[92.03-93.34]	DCS	ANDIS
5/MDH	76.02[73.29-78.61]	98.19[97.76-98.56]	ANDIS	GoDARTS
5/MDH	89.47[87.43-91.28]	96.36[95.77-96.89]	DCS	GoDARTS
5/MDH	85.41[82.19-88.24]	97.62[96.93-98.19]	GoDARTS	DCS

SIDD, Severe Insulin-Deficient Diabetes; SIRD, Severe Insulin-Resistant Diabetes cluster; MOD, Mild Obesity-related Diabetes; MD, Mild diabetes; MDH, Mild diabetes with high HDL-cholesterol.


## ESM Figures




**ESM Figure 1 GAP statistic and comparison to clusters based on HOMA2 measures** **a.** Number of clusters versus the GAP statistic in DCS, GoDARTS and ANDIS. The most optimal number of clusters was at five clusters indicated by the dotted line. **b.** Comparison of clustering in ANDIS in the current study versus those identified in Ahlqvist et al.[1]. Numbers on the diagonal represent the absolute overlap (upper number) and the percentage (lower number). In the right panel, the sensitivity and specificity are given with 95% confidence intervals. SIDD, Severe Insulin-Deficient Diabetes; SIRD, Severe Insulin-Resistant Diabetes cluster; MOD, Mild Obesity-related Diabetes; MD, Mild diabetes; MDH, Mild diabetes with high HDL-cholesterol.



**ESM Figure 2 Characteristics of the clusters for males and females separate.** **a.** Characteristics of the five clusters across three cohorts DCS (**a-e**), GoDARTS (**f-j**) and ANDIS (**k-o**). X-axis, cluster. Y-axis, age (**a, f, k**), BMI (**b, g, l**), HbA<sub>1c</sub> (**c, h, m**), HDL-cholesterol (**d, i, n**), and C-peptide (**e, j, o**). SIDD, Severe Insulin-Deficient Diabetes; SIRD, Severe Insulin-Resistant Diabetes cluster; MOD, Mild Obesity-related Diabetes; MD, Mild diabetes; MDH, Mild diabetes with high HDL-cholesterol. Red females, blue males.



**ESM Figure 3 All pairwise comparisons of identified clusters versus predicted clusters.** Top number in each cell represents the absolute overlap, the bottom number the percentage of individuals. Individuals were assigned to a cluster in cohort A based on the cluster centres of cohort B and compared to the clusters identified in the cohort A. This resulted in the following combinations: **a** clusters identified in DCS based on ANDIS centres **b** clusters identified in ANDIS based on DCS centres **c** clusters identified in ANDIS based on GoDARTS centres **d** clusters identified in GoDARTS based on ANDIS centres **e** clusters identified in GoDARTS based on DCS centres **f** clusters identified in DCS based on GoDARTS centres. SIDD, Severe Insulin-Deficient Diabetes; SIRD, Severe Insulin-Resistant Diabetes cluster; MOD, Mild Obesity-related Diabetes; MD, Mild diabetes; MDH, Mild diabetes with high HDL-cholesterol.



**ESM Figure 4 Hazard for time to insulin requirement across clusters. a SIDD, b SIRD, c MOD, d MD, e MDH.** X-axis, hazard ratio, y-axis cluster. Numbers in panels represent hazards with 95% confidence intervals.